Our new ThinkLive Commercialization event dedicated to topics that impact market access and commercialization strategy took place in early February 2021. Our brand new ABLive platform will enable on-demand access to the event through May, including the chance to meet one-one-one with the AmerisourceBergen team. Below are highlights and additional resources from the event.
Agenda highlights
- Hear from AmerisourceBergen leadership including Steve Collis and our commercialization leadership on unlocking product potential
- Listen in to a chat between AmerisourceBergen's Bob Mauch and Dr. Scott Gottlieb, former FDA commissioner
Learn outside perspectives from Wall Street with AmerisourceBergen's Leslie Donato and analysts from Baird and Deutsche Bank
- Understand new healthcare policy implications during a State of the Union session
Learn key considerations for manufacturers when commercializing cell and gene therapies,
new orphan or rare disease products, and COVID-19 vaccines and therapies- Gain detailed insights on strategies for specialty pharma and leveraging classes of trade
In The News
Meeting the commercialization challenge of a surging cell and gene therapy market
Undaunted by the challenges the COVID-19 pandemic unleashed on the world the expected surge of cell and gene therapies already in the pipeline and on the horizon will continue to materialize, and with them the complexity of riding that wave of innovation.
Commercialization in Canada: Navigating Complex Requirements to Drive Product Success
The Canadian pharmaceutical market, which is among the 10 largest worldwide, has long been viewed as a top-tier launch destination. However, the path to product commercialization in Canada is complex and can be challenging.
To successfully navigate the Canadian healthcare system, manufacturers should seek a partner with in-depth knowledge of the market that can help them design a commercialization strategy to drive product acceptance and success as quickly as possible.
To successfully navigate the Canadian healthcare system, manufacturers should seek a partner with in-depth knowledge of the market that can help them design a commercialization strategy to drive product acceptance and success as quickly as possible.
Addressing Disparities in Access: Designing Patient Support Programs to Close Gaps, Improve Health Outcomes
Recent research shows the COVID-19 pandemic has exacerbated racial and socioeconomic disparities in access to healthcare and health insurance. In fact, the uninsured rate among Black Americans climbed from 17 percent in February 2020 to 26 percent in September 2020.
Patient support programs are designed to remove barriers to care and help patients access, afford and remain on the treatment they need.
Cell and gene therapy: Creating connections amid complexity
Product developments in cell and gene therapy are both among the most groundbreaking and the most complex. Cell and gene therapy product launch success hinges on investment in the right technology and data solutions, and that also means finding the right partner.
COVID-19 Implications
Global Markets
Emerging Therapies
Cell and gene therapies: bringing innovation to market
With the potential of 40+ groundbreaking cell and gene therapy products FDA-approved by 2024, manufacturers are looking for innovative ways to successfully bring these therapies to market.
Join AmerisourceBergen experts for a webinar as they discuss commercialization considerations that manufacturers should know.
Biosimilars Pipeline Report: A guide for understanding the growing market
Biosimilars are a promising product category, one that can provide patients and doctors with more affordable treatment options. As this market matures, its pipeline continues to grow. This reference guide is a useful tool to visualize and understand the current product landscape and potential future of this emerging market.
Innovation
How to maximize your drug commercialization investments
You want to make the most of scientific advances and move health forward to change patient lives for the better. View our guide on what matters most at each stage of the product life cycle to making the most of your commercialization investments.
Speeding access to therapy with pharmacy eBV
As the payer landscape grows increasingly complex, manufacturers have to navigate new requirements at every juncture of the drug commercialization process. How manufacturers handle the intricate healthcare landscape could impact if and when patients can access the therapies they need.
Patient Experience
Rethink field services: Three myths keeping access barriers in front of your product
The current myths that may have the biggest impact on your product should you continue to believe them:
- Myth #1: I only need field services for buy-and-bill products
- Myth #2: Field services are only impactful in person
- Myth #3: Field services aren't designed for small pharma
Case study: an innovative field reimbursement program expands patient access
Learn how Xcenda designed and launched a best-in-class field reimbursement and access support program. Steps include:
- Make informed decisions
- Knowledgeable experts and useful tools
- Data-driven solutions
- Convenient access to online education
Patient support launch guide: competitive markets
Everything you need to know about utilizing patient support programs to launch your product in a competitive marketplace. You'll learn:
- How to leverage a proven program launch framework
- Key considerations for differentiating your new therapy in a competitive market
- Best practices for building and implementing a patient-centric support program
- Questions to ask when selecting a patient support partner for your new therapy
Patient support launch guide: novel therapies
Get actionable insights from Lash Group experts to help you learn how to ensure patient support success as an innovator in a therapeutic area. You’ll learn:
- How to leverage a proven program launch framework and key considerations at each phase
- The right resources to dedicate to your program launch
- The factors that can impact your launch timeline
- The questions to ask when selecting a patient support partner for your novel therapy
Data & Analytics
